Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HRT012
MIFTS: 53

Heart Valve Disease

Categories: Blood diseases, Cardiovascular diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Heart Valve Disease

About this section

MalaCards integrated aliases for Heart Valve Disease:

Name: Heart Valve Disease 12 15 62 17 70
Valvular Heart Disease 12 15
Heart Valve Diseases 42 44
Abnormality of the Heart Valves 6
Valvular Heart Diseases 54
Heart Valve Prolapse 44

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4079
NCIt 50 C45525
SNOMED-CT 67 368009 398995000
UMLS 70 C0018824 C0079485
Sources

Summaries for Heart Valve Disease

About this section
MedlinePlus : 42 Your heart has four valves. Normally, these valves open to let blood flow through or out of your heart, and then shut to keep it from flowing backward. But sometimes they don't work properly. If they don't, you could have Regurgitation - when blood leaks back through the valve in the wrong direction Mitral valve prolapse - when one of the valves, the mitral valve, has "floppy" flaps and doesn't close tightly. It's one of the most common heart valve conditions. Sometimes it causes regurgitation. Stenosis - when the valve doesn't open enough and blocks blood flow Valve problems can be present at birth or caused by infections, heart attacks, or heart disease or damage. The main sign of heart valve disease is an unusual heartbeat sound called a heart murmur. Your doctor can hear a heart murmur with a stethoscope. But many people have heart murmurs without having a problem. Heart tests can show if you have a heart valve disease. Some valve problems are minor and do not need treatment. Others might require medicine, medical procedures, or surgery to repair or replace the valve. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Heart Valve Disease, also known as valvular heart disease, is related to rheumatic heart disease and dilated cardiomyopathy, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Heart Valve Disease is SMC1A (Structural Maintenance Of Chromosomes 1A), and among its related pathways/superpathways are Inflammatory mediator regulation of TRP channels and Amoebiasis. The drugs Acetylcysteine and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include Heart, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A heart disease involving one or more of the four valves of the heart (the aortic and mitral valves on the left and the pulmonary and tricuspid valves on the right).

PubMed Health : 62 About heart valve disease: Heart valve disease occurs if one or more of your heart valves don't work well. The heart has four valves: the tricuspid (tri-CUSS-pid), pulmonary (PULL-mun-ary), mitral (MI-trul), and aortic (ay-OR-tik) valves. These valves have tissue flaps that open and close with each heartbeat. The flaps make sure blood flows in the right direction through your heart's four chambers and to the rest of your body.

Wikipedia : 73 Valvular heart disease is any cardiovascular disease process involving one or more of the four valves of... more...

Sources

Related Diseases for Heart Valve Disease

About this section

Diseases related to Heart Valve Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 333)
# Related Disease Score Top Affiliating Genes
1 rheumatic heart disease 32.3 TGFB1 NPPB IL1B CNMD
2 dilated cardiomyopathy 31.8 TGFB1 NR3C2 NPPB NPPA MIR499A IL1B
3 cardiovascular system disease 31.8 NR3C2 NPPB NPPA MIR499A MIR423 MIR29B1
4 arteries, anomalies of 31.2 MIR499A MIR423 MIR29B1 MIR21 MIR126 IL1B
5 mitral valve stenosis 31.2 NPPB NPPA MIR3909
6 mitral valve insufficiency 31.1 NR3C2 NPPB NPPA MIR423
7 lipoprotein quantitative trait locus 31.1 NPPB NPPA MIR499A MIR423 MIR29B1 MIR21
8 mitral valve disease 31.0 NPPB NPPA MIR423
9 heart septal defect 31.0 NPPA MIR499A MIR423
10 chronic kidney disease 30.9 TGFB1 NR3C2 NPPB NPPA MIR21 MIR126
11 migraine with or without aura 1 30.8 IL1B HTR2B HTR2A APOH
12 kidney disease 30.8 TGFB1 NR3C2 NPPB NPPA MIR21 MIR126
13 hypertrophic cardiomyopathy 30.8 TGFB1 NR3C2 NPPB NPPA MIR499A MIR21
14 pulmonary hypertension 30.7 NPPB NPPA MIR21 IL1B HTR2B HTR2A
15 sleep apnea 30.7 NPPB IL1B HTR2A
16 aortic valve disease 2 30.6 NPPB NPPA MIR423 MIR29B1 MIR21 MIR126
17 stroke, ischemic 30.6 NPPB NPPA IL1B APOH
18 respiratory failure 30.6 NPPB NPPA MIR126 IL1R1 IL1B
19 vascular disease 30.5 TGFB1 NPPB MIR21 MIR126 HTR2A APOH
20 pulmonary disease, chronic obstructive 30.5 TGFB1 NPPB MIR423 MIR21 MIR126 IL1B
21 diastolic heart failure 30.5 TGFB1 NPPB NPPA MIR499A
22 cerebrovascular disease 30.4 NPPB NPPA MIR21 APOH
23 pulmonary edema 30.4 NPPB NPPA IL1B
24 congestive heart failure 30.3 NR3C2 NPPB NPPA IL1B
25 disease by infectious agent 30.3 MIR29B1 MIR21 MIR126 IL1B
26 aortic disease 30.3 MIR423 MIR29B1 MIR21 MIR126
27 central nervous system disease 30.3 MIR423 MIR29B1 MIR21 MIR126 IL1B HTR2A
28 acute myocardial infarction 30.3 NPPB NPPA MIR499A MIR423 MIR21 MIR126
29 connective tissue disease 30.2 MIR423 MIR29B1 MIR21 MIR126 IL1B APOH
30 nervous system disease 30.2 MIR499A MIR423 MIR29B1 MIR21 MIR126 IL1B
31 heart disease 29.9 TGFB1 NR3C2 NPPB NPPA MIR499A MIR423
32 myocardial infarction 29.8 TGFB1 NR3C2 NPPB NPPA MIR499A MIR423
33 disproportionate short stature with ptosis and valvular heart lesions 11.2
34 cardiac valvular defect, developmental 11.2
35 tricuspid valve stenosis 11.1
36 andersen cardiodysrhythmic periodic paralysis 11.1
37 mucopolysaccharidosis, type iva 11.1
38 cardiomyopathy, familial hypertrophic, 21 11.1
39 coumarin resistance 11.0
40 cardiac valvular dysplasia, x-linked 11.0
41 tricuspid valve disease 11.0
42 cardiac tuberculosis 10.5 NR3C2 NPPB
43 vulvar vestibulitis syndrome 10.5 IL1R1 IL1B
44 lumbosacral lipoma 10.5 IL1R1 IL1B
45 indolent plasma cell myeloma 10.5 IL1R1 IL1B
46 idiopathic edema 10.5 NR3C2 NPPB NPPA
47 discrete subaortic stenosis 10.4 NPPA ADAMTS19
48 pyoderma 10.4 IL1R1 IL1B APOH
49 apnea, obstructive sleep 10.4 NR3C2 NPPB IL1B HTR2A
50 intracranial hypertension 10.4 NPPB IL1B APOH

Graphical network of the top 20 diseases related to Heart Valve Disease:



Diseases related to Heart Valve Disease
Sources

Symptoms & Phenotypes for Heart Valve Disease

About this section

UMLS symptoms related to Heart Valve Disease:


angina pectoris; chest pain; edema; undiagnosed heart murmur

GenomeRNAi Phenotypes related to Heart Valve Disease according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 9.64 TGFB1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-115 9.64 IL1R1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.64 IL1B IL1R1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-122 9.64 IL1R1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.64 IL1B IL1R1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-140 9.64 TGFB1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-143 9.64 TGFB1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.64 NR3C2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-168 9.64 IL1B IL1R1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-185 9.64 NR3C2
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-198 9.64 IL1B IL1R1 NR3C2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-25 9.64 IL1R1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 9.64 NR3C2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.64 IL1R1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-56 9.64 TGFB1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-70 9.64 NR3C2
Sources

Drugs & Therapeutics for Heart Valve Disease

About this section

PubMed Health treatment related to Heart Valve Disease: 62

Currently, no medicines can cure heart valve disease . However, lifestyle changes and medicines often can successfully treat symptoms and delay problems for many years. Eventually, though, you may need surgery to repair or replace a faulty heart valve. The goals of treating heart valve disease might include: Preventing, treating, or relieving the symptoms of other related heart conditions. Protecting heart valves from further damage. Repairing or replacing faulty valves when they cause severe symptoms or become life threatening. Replacement valves can be man-made or biological.

Drugs for Heart Valve Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 223)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
3
Remifentanil Approved Phase 4 132875-61-7 60815
4
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
5
Etomidate Approved Phase 4 33125-97-2 36339 667484
6
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
7
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
8
Sodium citrate Approved, Investigational Phase 4 68-04-2
9
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
10
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
11
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
13
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
14
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
15
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
16
Morphine Approved, Investigational Phase 4 57-27-2 5288826
17
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
18
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
19
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
20
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
21
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
22
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6, 59-43-8 1130
23
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
24
Simendan Investigational Phase 4 131741-08-7
25 Respiratory System Agents Phase 4
26 Antidotes Phase 4
27 Expectorants Phase 4
28 Antiviral Agents Phase 4
29 N-monoacetylcystine Phase 4
30 Serine Proteinase Inhibitors Phase 4
31 Antithrombin III Phase 4
32 Antithrombins Phase 4
33 HIV Protease Inhibitors Phase 4
34
protease inhibitors Phase 4
35 Antirheumatic Agents Phase 4
36 Anesthetics Phase 4
37 Cyclooxygenase Inhibitors Phase 4
38 Anti-Inflammatory Agents Phase 4
39 Anti-Inflammatory Agents, Non-Steroidal Phase 4
40 Anesthetics, Inhalation Phase 4
41 Platelet Aggregation Inhibitors Phase 4
42 Vecuronium Bromide Phase 4 50700-72-6
43 Cardiotonic Agents Phase 4
44 Phosphodiesterase 3 Inhibitors Phase 4
45 Phosphodiesterase Inhibitors Phase 4
46 Thiamin Phase 4
47 Fibrinolytic Agents Phase 4
48 Antipyretics Phase 4
49 Citrate Phase 4
50 Sildenafil Citrate Phase 4 171599-83-0

Interventional clinical trials:

(show top 50) (show all 303)
# Name Status NCT ID Phase Drugs
1 The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement. Unknown status NCT02710747 Phase 4
2 The ABC Trial - Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery Unknown status NCT01623193 Phase 4
3 Frailty and Cognitive Function Assessment of TAVI Patients (The Hungarian Frailty Score) - Observational, Prospective, Singe Center Study Unknown status NCT02650388 Phase 4
4 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
5 Prevention of Acute Kidney Injury by N-Acetylcystein in Patients Undergone Cardiac Valve Replacement Unknown status NCT03440268 Phase 4 N Acetyl Cysteine;Placebos
6 Phase 4 Study Comparing Albumin 5%, Hydroxyethylstrach 130/0.4 (6%) and Ringer Lactate for Volume Replacement During Cardiac Surgery Completed NCT01174719 Phase 4 volume replacement;Humanalbumin 5%;volume replacement
7 Effect of Propofol and Sevoflurane on Serum CD39 and CD73 Level After Open Heart Surgery With Cardiopulmonary Bypass Completed NCT02136979 Phase 4 Propofol;Sevoflurane
8 The Effect of Propofol on Tissue Doppler Imaging of Mitral Valve Annular Velocity During Remifentanil-based Cardiac Anesthesia Completed NCT01826149 Phase 4 Propofol 1.0mcg;Propofol 2.0mcg;Propofol 3.0mcg
9 Effect of Combined Remote Ischemic Preconditioning and Postconditioning on Acute Pulmonary Injury in Patients Undergoing Valvular Heart Surgery Completed NCT01427621 Phase 4
10 Beta Blockade in Mitral Regurgitation Completed NCT00166400 Phase 4 metoprolol succinate
11 Effect of Propofol on Renal Injury in Patients Undergoing Valvular Heart Surgery: A Prospective, Randomized Controlled Trial Completed NCT01384643 Phase 4 Propofol
12 Comparative Effects of Dexmedetomidine and Ketofol for Sedation in Out-patients Undergoing Diagnostic Trans-esophageal Echocardiography: A Randomized Controlled Trial Completed NCT02867930 Phase 4 Dexmedetomidine;Ketofol(ketamine+propofol)
13 The Effects of Levosimendan on Haemodynamics in Patients Undergoing Elective Aortic Valve Replacement (AVR)Together With Coronary Artery Bypass Grafting Completed NCT01210976 Phase 4 levosimendan;placebo
14 Sildenafil for Improving Outcomes After Valvular Correction Completed NCT00862043 Phase 4 Sildenafil Citrate;Placebo
15 The Ontario Multidetector Computed Tomography (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
16 Effectiveness of Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Aortic and Mitral Valvular Atrial Fibrillation Patients Completed NCT02982850 Phase 4 Dabigatran;Acetylsalicylic acid;Warfarin
17 Hypertonic Saline for Fluid Resuscitation After Cardiac Surgery Completed NCT03280745 Phase 4 Hypertonic saline;0.9% saline
18 The Changes in Cortisol Levels and Stress Responses During Cardiac Surgery. The Comparison Between Two Induction Agents: Etomidate and Thiopentone. Completed NCT01495949 Phase 4 etomidate;thiopentone
19 Randomized Isoflurane and Sevoflurane Comparison in Cardiac Surgery: A Prospective Randomized Clinical Trial. Completed NCT01477151 Phase 4 Volatile anesthetic
20 Different Modalities of Analgesia in Open Heart Surgeries in Mansoura University: Randomized Prospective Comparative Study Recruiting NCT04223219 Phase 4 Fentanyl;Fentanyl, Propofol;Dexmedetomidine, Ketamine, Magnesium sulfate
21 Anticoagulation Treatment Influence on Post-operative Patients -Action SJM EPIC Trial Withdrawn NCT00187304 Phase 4
22 Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications Unknown status NCT01000233 Phase 2, Phase 3
23 "Salvage Use" of Recombinant Activated Factor VII After Inadequate Haemostatic Response to Conventional Therapy in Complex Cardiac Surgery - a Randomised Placebo Controlled Trial Unknown status NCT00214656 Phase 3 Recombinant Activated Factor VII
24 Perioperative Infusion of Dexmedetomidine Improves Outcomes of Cardiovascular Surgery Completed NCT02237495 Phase 2, Phase 3 dexmedetomidine;placebo
25 Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair Completed NCT02084069 Phase 3 Atorvastatin
26 Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial Completed NCT02833948 Phase 3 Acetylsalicylic acid;Clopidogrel;Rivaroxaban
27 Risk Reduction of Symptomatic and Silent Brain Infarctions During Cardiac Surgery Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring Completed NCT01591018 Phase 3
28 Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve (BICATOR) Completed NCT02679261 Phase 3 Atorvastatin;Placebo
29 The Safety and Effectiveness of the SAPIEN 3 and SAPIEN 3 Ultra Valve in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification Who Are Not Candidates for Standard Mitral Valve Surgery. Recruiting NCT04408430 Phase 2, Phase 3
30 Clinical Trial Comparing a Conventional Median Sternotomy Versus a Minimally Invasive Technique for Aortic Valvular Replacement in Adults Terminated NCT00221663 Phase 2, Phase 3
31 Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis Terminated NCT03566303 Phase 2, Phase 3 Rivaroxaban 15 mg;Warfarin
32 Magnesium for the Prevention of Atrial Arrhythmias After Cardiac Surgery Terminated NCT00250965 Phase 3 intravenous magnesium
33 Prolongation of the Interval Between Prothrombin Time Tests in Stable Patients II (the PRINT II Study): a Randomized Controlled, Non-inferiority Trial Comparing 4-weekly With 12-weekly Testing and Dose-assessment Withdrawn NCT01654042 Phase 3
34 Cardiac Operation Under Totally Endoscope and Cardiopulmonary Bypass, a Single Center's Experience Unknown status NCT00921596 Phase 1, Phase 2
35 Bicuspid Aortic Valve Stenosis and the Effect of vItamin K2 on Calciummetabolism on 18F-NaF PET/MRI (BASIK2): a Pilot Study Unknown status NCT02917525 Phase 2
36 The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS) Applied on Cardiac Surgery With Cardiopulmonary Bypass: a Single Center, Randomized, Controlled Clinical Study Completed NCT02479581 Phase 2
37 N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement. Completed NCT01704482 Phase 2 N-acetylcysteine;placebo
38 Prevention of Renal Failure by Nitric Oxide in Prolonged Cardiopulmonary Bypass: A Double Blind Randomized Controlled Trial. Completed NCT01802619 Phase 1, Phase 2
39 CopenHeartVR - A Randomized Clinical Trial Investigating the Effect of Integrated Rehabilitation Versus Usual Care Without Physical Exercise After Heart Valve Surgery. Completed NCT01558765 Phase 2
40 Cytokine Clearance With Cytoabsorbant Device During Cardiac Bypass: a Pilot Study Completed NCT02775123 Phase 1, Phase 2
41 Passive Leg Raising Test to Predict Hypotension During Induction of Anesthesia in Patients Undergoing Cardiac Surgery Completed NCT01144546 Phase 2
42 Custodiol-HTK Solution as a Cardioplegic Agent- A Prospective Non-Inferiority Randomized Clinical Trial Completed NCT01681095 Phase 2 Custodiol HTK;Cold Blood Cardioplegia
43 A Prospective, Randomized, Multicenter Clinical Study on the High Vacuum Body Cavity Drainage Systems Following Open Heart Surgery Completed NCT00581399 Phase 2
44 Nitric Oxide Supplementation to the Extracorporeal Circulation Line as a Method of Nephroprotection in Cardiac Surgery Completed NCT03527381 Phase 1, Phase 2 Nitric Oxide
45 Phase II Study of Double Versus Single Reinitiation Dose of Warfarin After Interruption for Surgery Completed NCT01348074 Phase 2 Double dose
46 A Randomized Double-blind Study of 4-weekly Versus 12-weekly Monitoring of Stable Patients on Long-term Anticoagulation With Warfarin Completed NCT00356759 Phase 2 Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times
47 A Randomised Controlled Trial of Pre-surgery Sodium ValpRoate, for the Prevention of Organ Injury in Cardiac Surgery: THE Val-CARD TRIAL Recruiting NCT03825250 Phase 1, Phase 2 Sodium Valproate
48 A Multicenter, Double-blind, Placebo-controlled, Stratified-randomized, Parallel, Therapeutic Exploratory Clinical Study to Evaluate the Efficacy and Safety of DA-1229 in Patients With Calcific Aortic Valve Disease Recruiting NCT04055883 Phase 2 DA-1229
49 A Phase 2, Randomized, Open Label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban Compared With Vitamin K Antagonism in Patients With Atrial Fibrillation With Bioprosthetic Mitral Valves - RIVER Active, not recruiting NCT02303795 Phase 2 Rivaroxaban;Warfarin
50 A Randomized Study of the Effects of Perioperative i.v. Ketorolac-lidocaine on the Hemodynamic Response in the Patients With Valvular Heart Diseases During Cesarean Delivery Suspended NCT01571791 Phase 2 Placebo;Ketorolac-Lidocaine

Search NIH Clinical Center for Heart Valve Disease

Cochrane evidence based reviews: heart valve diseases

Sources

Genetic Tests for Heart Valve Disease

About this section
Sources

Anatomical Context for Heart Valve Disease

About this section

MalaCards organs/tissues related to Heart Valve Disease:

40
Heart, Endothelial, Bone, Liver, Kidney, Bone Marrow, Breast
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Heart Valve Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Atrioventricular Valves Atrioventricular Valve Cells Affected by disease
2 Heart Semilunar Valves Semilunar Valve Cells Affected by disease
Sources

Publications for Heart Valve Disease

About this section

Articles related to Heart Valve Disease:

(show top 50) (show all 6126)
# Title Authors PMID Year
1
Associations of long-term exposure to traffic-related air pollution with risk of valvular heart disease based on a cross-sectional study. 61 42
33348255 2021
2
BIRC5, GAJ5, and lncRNA NPHP3-AS1 Are Correlated with the Development of Atrial Fibrillation-Valvular Heart Disease. 61 42
33518654 2021
3
Trace elements in patients with aortic valve sclerosis. 42
33627011 2021
4
A prospective study of brain natriuretic peptide levels in three subgroups: Stroke with hypertension, stroke without hypertension, and hypertension alone. 54 61
20436747 2010
5
Can measurement of B-type natriuretic peptide levels improve cardiovascular disease prevention? 54 61
18307738 2008
6
Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. 54 61
17345160 2007
7
[PTEN/PI3K pathways are involved in the signal transduction of myocardial remodeling in patients with congestive heart failure]. 54 61
16029597 2005
8
Comparison of positive cases for B-type natriuretic peptide and ECG testing for identification of precursor forms of heart failure in an elderly population. 54 61
16043943 2005
9
Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart. 54 61
15721858 2005
10
Perioperative changes in atrial natriuretic peptide plasma levels associated with mitral and aortic valve replacement. 61 54
14973795 2004
11
Cardiotrophin-1: expression in experimental myocardial infarction and potential role in post-MI wound healing. 54 61
14674704 2003
12
Cardiac valvular disease in patients with systemic lupus erythematosus. Relationship with anticardiolipin antibodies. 61 54
14677016 2003
13
Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. 54 61
14608520 2003
14
3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. 54 61
12761331 2003
15
Antiphospholipid antibodies and the risk of thromboembolic events in valvular heart disease. 54 61
12630582 2003
16
Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. 61 54
12466135 2002
17
Locally different role of atrial natriuretic peptide (ANP) in the pericardial fluid. 54 61
12270761 2002
18
Brain natriuretic peptide is a sensitive indicator of impaired left-ventricular function in elderly patients with cardiovascular disease. 54 61
9286500 1997
19
Effect of the maze procedure for atrial fibrillation on atrial and brain natriuretic peptide. 61 54
9104915 1997
20
Elevated anticardiolipin antibodies in a patient with vibration-white-finger, valvular heart disease and psoriatic arthritis. 61 54
8467615 1993
21
Comparative study of atrial peptides ANF (1-98) and ANF (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. 61 54
8451600 1993
22
Anticardiolipin antibody and stroke: possible relation of valvular heart disease and embolic events. 54 61
1611635 1992
23
Anticardiolipin antibody and stroke: possible relation of valvular heart disease and embolic events. 61 54
1933972 1991
24
Lack of association between anticardiolipin antibodies and heart valve disease in Chinese patients with systemic lupus erythematosus. 61 54
1975008 1990
25
Cardiovascular severe maternal morbidity in pregnant and postpartum women: development and internal validation of risk prediction models. 61
32946639 2021
26
Transcatheter aortic valve replacement after chest radiation: A propensity-matched analysis. 61
33359282 2021
27
[Telemedicine for patients with valvular heart disease or aortic disease in the era of COVID-19]. 61
33199935 2021
28
[Telemedicine for patients with valvular heart disease or aortic disease in the era of COVID-19. Response]. 61
33288972 2021
29
Telemedicine for patients with valvular heart disease or aortic disease in the era of COVID-19. 61
33455891 2021
30
Telemedicine for patients with valvular heart disease or aortic disease in the era of COVID-19. Response. 61
33495069 2021
31
Cost of inpatient heart failure care and 30-day readmissions in the United States. 61
33321128 2021
32
Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis. 61
33336426 2021
33
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation and valvular heart disease. 61
33538623 2021
34
The effect of treated apical periodontitis before heart valve surgery on C-reactive protein levels. 61
32710519 2021
35
Changes in Cardiac Structure and Function Before and After Renal Transplantation: A Longitudinal Study. 61
33602526 2021
36
A review of the immune response stimulated by xenogenic tissue heart valves. 61
33372305 2021
37
Evolution of Transcatheter Aortic Valve Replacement | Review of Literature. 61
32522375 2021
38
Hospitalization deficit of in- and outpatient cases with cardiovascular diseases and utilization of cardiological interventions during the COVID-19 pandemic: Insights from the German-wide helios hospital network. 61
33497509 2021
39
Successful Preoperative Optimization for Lung Transplantation With Transcatheter Mitral Valve Repair. 61
32652070 2021
40
Incidence, predictors and mortality risk of new heart failure in patients hospitalised with atrial fibrillation. 61
33707226 2021
41
Atrial Fibrillation in Valvular Heart Disease. 61
33516389 2021
42
Incident Strokes Among American Indian Individuals With Atrial Fibrillation. 61
33653124 2021
43
Infective Endocarditis as the Cause of Death: A Populationbased Study in Portugal, from 2002 to 2018. 61
33687320 2021
44
Infective endocarditis in patients with solid organ transplantation. A nationwide descriptive study. 61
33685806 2021
45
Impact of diabetes in patients waiting for invasive cardiac procedures during COVID-19 pandemic. 61
33757510 2021
46
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial. 61
33685502 2021
47
Comprehensive analysis of autophagy-related genes and patterns of immune cell infiltration in valvular atrial fibrillation. 61
33706714 2021
48
Relation of Left Atrial Enlargement to Subsequent Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients With Low to Borderline Embolic Risk. 61
33359192 2021
49
Valvular Heart Disease in Pregnancy: Anticoagulation and the Role of Percutaneous Treatment. 61
32868039 2021
50
Exercise Participation for Patients with Valvular Heart Disease: a Review of the Current Guidelines. 61
33740173 2021
Sources

Variations for Heart Valve Disease

About this section

ClinVar genetic disease variations for Heart Valve Disease:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SMC1A NM_001281463.1(SMC1A):c.730_732AAG[2] (p.Lys246del) Microsatellite Pathogenic 180197 rs727503773 GRCh37: X:53439900-53439902
GRCh38: X:53412950-53412952
Sources

Expression for Heart Valve Disease

About this section
Search GEO for disease gene expression data for Heart Valve Disease.
Sources

Pathways for Heart Valve Disease

About this section

Pathways related to Heart Valve Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Inflammatory mediator regulation of TRP channels 36
Show member pathways
 11.74 IL1R1 IL1B HTR2B HTR2A
2
Amoebiasis 36
11.55 TGFB1 IL1R1 IL1B
3
MicroRNAs in cancer 36
11.51 MIR423 MIR29B1 MIR21 MIR205 MIR126
4
Th17 Differentiation Pathway 64
Show member pathways
 11.46 TGFB1 IL1R1 IL1B
5
MicroRNAs in cardiomyocyte hypertrophy 1
Show member pathways
 11.46 TGFB1 NPPB NPPA CTF1
6
IL-9 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types 64
10.34 TGFB1 IL1B
Sources

GO Terms for Heart Valve Disease

About this section

Cellular components related to Heart Valve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 TGFB1 NPPB NPPA IL1R1 IL1B CTF1
2 extracellular space GO:0005615 9.36 TGFB1 NPPB NPPA MIR423 MIR29B1 MIR21
3 G protein-coupled serotonin receptor complex GO:0098666 8.96 HTR2B HTR2A

Biological processes related to Heart Valve Disease according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 TGFB1 MIR21 IL1B HTR2B HTR2A CTF1
2 cytokine-mediated signaling pathway GO:0019221 9.96 TGFB1 IL1R1 IL1B CTF1
3 positive regulation of cell migration GO:0030335 9.93 TGFB1 MIR29B1 MIR21 IL1B
4 cellular calcium ion homeostasis GO:0006874 9.83 TGFB1 HTR2B HTR2A
5 positive regulation of inflammatory response GO:0050729 9.82 MIR21 MIR126 IL1B
6 cellular response to mechanical stimulus GO:0071260 9.79 TGFB1 NPPA IL1B
7 negative regulation of angiogenesis GO:0016525 9.78 NPPB MIR21 CNMD APOH
8 positive regulation of MAP kinase activity GO:0043406 9.77 TGFB1 HTR2B HTR2A
9 positive regulation of fat cell differentiation GO:0045600 9.76 MIR29B1 MIR21 HTR2A
10 positive regulation of blood vessel endothelial cell migration GO:0043536 9.75 TGFB1 MIR499A MIR126
11 positive regulation of cell division GO:0051781 9.72 TGFB1 IL1B HTR2B
12 positive regulation of epithelial to mesenchymal transition GO:0010718 9.71 TGFB1 MIR21 IL1B
13 negative regulation of endothelial cell proliferation GO:0001937 9.69 MIR21 CNMD APOH
14 miRNA mediated inhibition of translation GO:0035278 9.67 MIR499A MIR29B1 MIR21 MIR205
15 behavior GO:0007610 9.65 HTR2B HTR2A
16 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.65 MIR29B1 MIR21
17 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.65 TGFB1 MIR21 MIR126 HTR2B HTR2A
18 negative regulation of systemic arterial blood pressure GO:0003085 9.64 NPPB NPPA
19 positive regulation of cardiac muscle cell differentiation GO:2000727 9.63 TGFB1 MIR499A
20 cGMP biosynthetic process GO:0006182 9.62 NPPB NPPA
21 receptor guanylyl cyclase signaling pathway GO:0007168 9.61 NPPB NPPA
22 regulation of calcium ion transmembrane transport via high voltage-gated calcium channel GO:1902514 9.61 NPPA MIR21
23 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.6 MIR21 APOH
24 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.57 IL1R1 IL1B
25 regulation of blood vessel remodeling GO:0060312 9.56 TGFB1 MIR29B1
26 positive regulation of potassium ion export across plasma membrane GO:1903766 9.52 NPPA MIR21
27 positive regulation of vascular endothelial cell proliferation GO:1905564 9.5 MIR499A MIR21 MIR126
28 gene silencing by miRNA GO:0035195 9.5 MIR499A MIR423 MIR3909 MIR29B1 MIR21 MIR205
29 regulation of aorta morphogenesis GO:1903847 9.46 MIR29B1 MIR205
30 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.43 HTR2B HTR2A
31 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.4 HTR2B HTR2A
32 cGMP-mediated signaling GO:0019934 9.33 NPPB NPPA HTR2B
33 positive regulation of metalloendopeptidase activity GO:1904685 8.8 MIR29B1 MIR21 MIR205

Molecular functions related to Heart Valve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.46 MIR29B1 MIR21 MIR205 MIR126
2 serotonin binding GO:0051378 9.32 HTR2B HTR2A
3 hormone receptor binding GO:0051427 9.26 NPPB NPPA
4 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR499A MIR423 MIR3909 MIR29B1 MIR21 MIR205
5 Gq/11-coupled serotonin receptor activity GO:0001587 8.96 HTR2B HTR2A
Sources

Sources for Heart Valve Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....